We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FTC DROPS INVESTIGATION OF GENZYME/NOVAZYME MERGER
FTC DROPS INVESTIGATION OF GENZYME/NOVAZYME MERGER
January 16, 2004
Drug companies which have competing preclinical research programs for rare diseases and are looking to merge should look to the FTC’s recent decision to close its investigation into Genzyme’s 2001 acquisition of Novazyme Pharmaceuticals as a possible precedent setting move by the commission.